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In this  issue  of  Vaccine,  the maternal  immunization  platform  as  an  approach  to protect  mothers  and  infants
against  diverse  pathogens  is  presented.  Potential  vaccine  targets  and  the  safety,  science,  trial  designs,  eth-
ical considerations,  and  international  perspectives  focusing  on low  and  middle  income  countries  (LMIC)nﬂuenza vaccine
ertussis vaccine
are  discussed.  This  information  provides  a timely  update  because  maternal  immunization  is  increasingly
being  considered  as an  intervention  to  prevent  maternal  and/or  neonatal  disease.  Prioritization  of  vaccine
targets  for maternal  immunization  by  researchers,  public  health  ofﬁcials  and  health  care  workers  needs
to begin  now.
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s an approach to protect mothers and infants against diverse
athogens is discussed and the science, trial designs, ethical
onsiderations, and international perspectives focusing on low
nd middle income countries (LMIC) are reviewed. This informa-
ion provides a timely update because maternal immunization is
ncreasingly being considered as a potential intervention to pre-
ent maternal and/or neonatal disease. Simultaneously, lessons
earned from both older clinical studies and recent immunization
mplementation programs in pregnant women must be appreci-
ted. Immunization during pregnancy to protect both the woman
nd her infant is not new [1,2]; maternal immunization programs to
rotect against maternal and neonatal tetanus have been proven to
e effective [3] and have been ongoing for decades. Although ear-
ier studies were not always conducted with the rigor of current
rials, lessons learned from both old and new studies conducted for
ertussis [4,5] inﬂuenza [1,6], as well as Hemophilus inﬂuenza type
 polysaccharide and conjugate vaccines [7] should be taken into
ccount as the ﬁeld moves forward.
Worldwide maternal immunization programs utilizing tetanus
oxoid vaccines began in the 1980s based on high rates of mortality
ocumented in many developing countries from tetanus disease
n both mothers and infants following childbirth [3]. Maternal
mmunization remains an important tool – but not the only tool
 for preventing both maternal and neonatal tetanus in developing
ountries where the risk of acquiring tetanus during childbirth is
igh [8]. Tetanus immunization during pregnancy is currently an
mportant tool, particularly in countries where no tetanus vaccines
fter the infant series are administered. A marked decline in neon-
atal tetanus has been documented over the past decades, although
he persistence of neonatal tetanus indicates the need to continue
fforts to combat this preventable disease.
Increased rates of morbidity and mortality in pregnant women,
articularly in the third trimester of pregnancy, were documented
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.084
264-410X/© 2015 The Author. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
following infection with the 2009–2010 pandemic strains of
inﬂuenza A/H1N1 and documented in many countries [9]. Disease
in pregnant women in this century was  reminiscent of descrip-
tions of pandemic disease going back to 1918 [10]. Risks to the
fetus due to preterm onset of labor, although not active infection,
were also documented during this recent pandemic [11,12]. No evi-
dence of fetal priming or sensitization following maternal inﬂuenza
or tetantus vaccination has been documented. The public health
response to this increased disease burden in pregnant women
resulted in priority for immunization of pregnant women with
inactivated inﬂuenza vaccines in many high-income countries. Sub-
sequently, the safety and effectiveness of this approach has been
reported and the analysis of this approach to prevent inﬂuenza-
related morbidity and mortality in mothers and infants explored at
nationally and internationally [11–13]. Recently, a study supported
by the Bill and Melinda Gates Foundation in South Africa docu-
mented the safety and efﬁcacy of maternal inﬂuenza vaccine during
the post-pandemic period [14]. Descriptions of maternal inﬂuenza
immunization from the perspective of tropical countries and the
WHO will be presented in this issue.
Maternal immunization has also been advocated as an impor-
tant strategy to prevent neonatal pertussis in the USA and United
Kingdom due to increasing morbidity and mortality from neonatal
pertussis disease [15,16]. Recommendations for the use of acellular
pertussis vaccines and combination vaccines to pregnant women
were based on the presence of fatal cases of pertussis in young
infants. At the time these recommendations were made, little data
was available on the safety and efﬁcacy of maternal immuniza-
tion on the subsequent immune response to vaccination in infants.
After the implementation of this approach, the effectiveness as well
as the safety, immunogenicity, antibody transfer, and impact on
infant immunization was demonstrated [6,16]. The potential appli-
cation of this approach in low and middle income countries will be
explored in this issue.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The increased acceptance of immunization to prevent inﬂuenza
n pregnant women represented a shift in the acceptance of mater-
al immunization in many countries. The use of maternal acellular
ertussis vaccine to prevent severe neonatal disease represents
nother important paradigm shift because the rationale for mater-
al pertussis vaccination is chieﬂy to protect the infant, not the
other. However, both mothers and infants have potential ben-
ﬁt from inﬂuenza or pertussis vaccines, and both vaccines are
nown to be safe, well tolerated, and immunogenic in adults. For
oth pathogens, maternal immunization programs were instituted
ecause of overwhelming epidemiological evidence of the burden
f disease and public health and community acceptance that this
isk was high. This increasing interest in and utilization of maternal
accines demonstrates the potential beneﬁt but also the new chal-
enges to those involved in communication about research issues,
s well as health care providers caring for pregnant women, public
ealth agencies, regulatory authorities, and pharmaceutical com-
anies.
New questions regarding maternal immunization are being
aised. Obstetricians, midwives, and other healthcare workers car-
ng for pregnant women are becoming more interested in maternal
mmunization but nonetheless want to know, how many vaccines
an we give these women? How can future trials of new mater-
al vaccines be conducted when the standard of care is already to
dminister at least one vaccine? What new targets should receive
riority? If multiple new maternal vaccines are developed and
hown to be safe and effective, which vaccine(s) should have pri-
rity? The development of new maternal vaccines is dependent on
he availability of a safe, immunogenic, and effective product but
ore importantly, the epidemiology of the target pathogen in rep-
esentative countries or populations must be ascertained, and the
rue burden of disease in the mother and infant characterized. Lack
f data characterizing the true risk of infections in the ﬁrst month
f life is profound, particularly in developing countries where hos-
ital access may  be limited and surveillance of disease is linked to
hose children surviving long enough to actually reach the hospital.
he true burden of disease and mortality due to neonatal pertussis,
espiratory syncytial virus (RSV), and Group B streptococcus (GBS)
emain relatively poorly characterized in many parts of the world
oday. The potentially devastating impact and long term sequelae
f infections with cytomegalovirus, herpes simplex virus, and toxo-
lasmosis are similarly not appreciated in many LMIC but argue for
onsideration of vaccination strategies including but not limited to
aternal immunization.
Future maternal immunization targets, vaccines, and policies
equire an assessment of risks and potential beneﬁts. The tempt-
ng application of maternal immunization platform as a panacea
o all potential neonatal infections must be weighed in terms of
he burden of disease, the work and time involved for those pro-
iding prenatal care, the cost-effectiveness of such interventions,
nd the safety, beneﬁts, and risks of this approach. Safety consider-
tions remain paramount although data remain reassuring to date
17]. Even the relatively limited epidemiological data from many
eveloping countries might demonstrate the likelihood of moder-
te to marked potential beneﬁt to infants if partial reduction in
eonatal disease due to CMV, GBS, or RSV could be demonstrated;
onversely, rates of neonatal disease may  vary depending on the
etting, the medical system available, or rates of coinfection with
IV or tuberculosis. Other potential targets for maternal immuniza-
ion include malaria, meningococcus, pneumococcus, tuberculosis,
r even rabies. The potential beneﬁt to infants may  be demon-
trated even if pathogen-speciﬁc attack rates are relatively low
ecause sequelae of these infections can be severe. Costs for procur-
ng, storing, administering, and documenting vaccines for pregnant
omen may  be considerable, with potentially lower direct mater-
al beneﬁt. A relatively low burden of neonatal disease combined(2015) 6372–6373 6373
with an expensive vaccine or one not easily stored and adminis-
tered may  not be worthwhile.
Increasing rates of routine prenatal care for pregnant women is a
world health goal being actively promoted; the workload of nurses
and clinical staff already overworked in prenatal clinics in LMIC
may  be nearly maximized in some settings. Additional support for
prenatal clinics in developing countries may  require increased sup-
port for maternal health care overall. Nonetheless, the potential
for maternal immunization to protect the mother and infant needs
serious consideration. Prioritization of vaccine targets for mater-
nal immunization by researchers, public health ofﬁcials and health
care workers needs to begin now.
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